This is a private, research-focused community. Evidence-based peptides, nootropics & research chems. RUO educational only. All claims/statements are our own.
Joined December 2024
- Tweets6.5K
- Following2.2K
- Followers3.2K
- Likes7.7K
Pinned Tweet
Just a quick, permanent reminder for everyone following along.
The brands we discuss may offer affiliate compensation or discounts on research products and materials. However:
Everything we write — research summaries, interpretations, opinions, and any product commentary — is developed completely independently by the ELEVATE research community.
No brand, manufacturer, or supplier reviews, approves, edits, or directs any of it. Ever. In fact, the opposite is frequently true.
If anyone makes a statement about a product on this page, that statement is solely the view of the independent researcher who posted it. It is never the claim, position, endorsement or representation of any manufacturer, supplier, or brand.
The compounds discussed here are research chemicals intended strictly for laboratory and research use only.
They are not for human consumption. Any discussion of published studies, mechanisms, results, or product graphics is purely educational and informational.
None of it constitutes medical advice, nor is it a recommendation, suggestion, or endorsement of non-research human use.
All statements on this page reflect our independent research community’s analysis only. Variables exist in every research setting.
Never treat any post, thread, graphic, or comment as the manufacturer’s position or as guidance for personal use.
Appreciate y’all. Keep on researching.
Imeglimin: What the Research Shows elevateresearch.blog/2026/10…
For a little clarity. These peptides are not all of a sudden “legal”.
HHS just dropped major interim guidance on peptide compounding.
On Oct 28, 2026, HHS released an Enforcement Discretion Policy for 503A compounding of six peptide bulk substances while FDA continues formal rulemaking for the 503A bulks list.
This is not FDA approval, not addition to the bulks list, and not permanent.
It is a temporary “we won’t enforce against you if you follow these rules” stance for state-licensed 503A pharmacies, federal facilities, and licensed physicians doing patient-specific compounding.
The six peptides:
•BPC-157
•TB-500
•MOTS-c
•KPV
•Semax
•Epitalon
These match the ones the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend for the bulks list in July 2026 (votes were close; FDA staff had recommended against).
They were previously in Category 2 until April 2026.
What the policy actually requires (key conditions):
•Bulk substance from an FDA-registered (section 510) facility that is CGMP-compliant, with a valid CoA showing identity, purity, potency, and absence of harmful contaminants (endotoxin, microbial, residual solvents, etc.).
•Single active ingredient only (no combos).
•Patient-specific prescription required (classic 503A).
•Specific routes only (examples: BPC-157 subq/IM/oral/topical; Semax intranasal; KPV topical/oral; others mostly injectable; oral forms need documented human bioavailability data).
•Serious adverse events and quality issues must be reported to FDA MedWatch + relevant states.
•Labeling must state it’s a compounded product and “Not for resale.”
•Only co-packaged with FDA 510(k)-cleared syringes.
•Must still comply with all other applicable FD&C Act requirements (no insanitary conditions, etc.).
HHS can revisit or pull the policy if safety signals or product-quality problems emerge. It does not cover 503B outsourcing facilities, research-use-only channels, or supplements. State boards can still restrict or ban these compounds.
Why this is happening: Officials cite significant patient interest, lack of approved products, and the desire to shift people away from unregulated foreign RUO peptides that carry higher contamination and identity risks, toward supervised compounding with better quality controls and adverse-event tracking.
This is a practical interim step, not a free-for-all. Formal rulemaking to actually add (or reject) these on the 503A bulks list is still ahead and can take a long time.
Enforcement discretion can disappear quickly if data or politics shift.
For anyone in the research space: this is specifically about licensed 503A compounding for identified patients under prescription. It does not change the status of research-grade materials or create a general “peptides are now legal to sell” situation.
hhs.gov/sites/default/files/…
Looking for actual research on peptides, nootropics, metabolic compounds and more?
I’ve built an extensive, and growing Compound Index on ELEVATE Research, packed with educational articles, pharmacology, mechanisms of action, clinical studies, and emerging research.
No hype. No miracle claims. No “guides” Just a deeper look into the science behind compounds that deserve more attention.
Whether you’re new to this space or have been researching for years, there’s plenty to explore.
The index is constantly growing daily.
elevateresearch.blog/compoun…
#ELEVATEresearch #Peptides #Nootropics #Longevity #Research
Could CE-123 be one of the most underrated nootropics in research?
I genuinely think it deserves more attention.
Everyone talks about modafinil, armodafinil, and the usual dopamine-targeting compounds, but CE-123 is an interesting molecule that rarely gets discussed.
CE-123 is a synthetic modafinil analog developed as a more selective dopamine transporter (DAT) inhibitor.
And its pharmacology is where things get interesting.
Unlike traditional stimulants that can influence multiple neurotransmitter systems, CE-123 demonstrates relatively selective inhibition of dopamine reuptake, with minimal activity at norepinephrine and serotonin transporters in laboratory testing.
Essentially, researchers were investigating whether they could improve cognitive performance through more targeted dopaminergic modulation.
Here’s what makes CE-123 stand out.
1. Cognitive flexibility
A 2018 study found that CE-123 improved cognitive flexibility in rats performing attentional set-shifting tasks.
The animals demonstrated better ability to adapt when task rules changed.
Interestingly, CE-123 didn’t produce the same increase in premature responding observed with R-modafinil under one of the study’s testing conditions.
2. Memory acquisition and retrieval
Another 2018 study demonstrated improvements in spatial memory acquisition and retrieval.
Researchers also observed changes in hippocampal dopamine receptor expression, particularly D1 receptors.
This suggests its effects may extend beyond simply promoting wakefulness.
3. Motivation and effort
A 2019 study investigated S-CE-123 in effort-based behavioral tasks.
The compound increased willingness to perform demanding tasks for rewards and partially reversed motivational deficits induced by dopamine depletion.
That’s particularly interesting because motivation and cognitive performance aren’t necessarily the same thing.
4. Brain penetration
A 2023 pharmacokinetic study compared S-CE-123 with R-modafinil.
S-CE-123 demonstrated approximately fivefold higher unbound brain-to-plasma concentration ratios.
However, it was also metabolized considerably faster in liver experiments.
Better brain penetration doesn’t automatically mean a better drug, but it’s an interesting pharmacokinetic distinction.
5. Aging and cognitive decline
Perhaps my favorite finding comes from research involving aged rats.
S-CE-123 improved performance in certain reward-motivated cognitive tasks, while younger animals didn’t demonstrate the same improvements.
That raises an interesting possibility: compounds like CE-123 might have greater utility when dopaminergic function is compromised rather than already operating normally.
Now the important limitations.
CE-123 remains an experimental research compound.
There are no established human cognitive benefits, clinical dosing standards, or comprehensive human safety data.
And the results aren’t universally positive. Some studies found improvements in motivation without corresponding improvements in attention or spatial learning.
We also can’t assume its selectivity eliminates cardiovascular, sleep, dependence, or other stimulant-related risks.
Still, the research is fascinating.
A modafinil-derived compound with selective DAT inhibition, promising preclinical findings involving memory and cognitive flexibility, and potentially interesting applications in age-related cognitive dysfunction?
That’s exactly the kind of compound I think deserves more scientific attention.
Not because it’s proven superior to modafinil.
But because its pharmacology raises questions worth investigating.
CE-123 might be one of the more overlooked experimental nootropics out there.
What do you think? Underrated research compound or another promising molecule that won’t translate beyond animal studies?
For research discussion only. Not medical advice.
#CE123 #Nootropics #Neuroscience #CognitiveEnhancement #Dopamine #Modafinil #BrainHealth #Longevity #Elevateresearh
What if blocking a single inflammatory signaling molecule could extend lifespan by approximately 25%?
That’s exactly what researchers observed in mice.
A 2024 study published in Nature by Widjaja and colleagues investigated interleukin-11 (IL-11), an inflammatory signaling protein associated with aging, fibrosis, and metabolic dysfunction.
The results were impressive.
Researchers used two different approaches.
First, mice genetically lacking IL-11 lived approximately 24.9% longer on average.
Second, normal mice receiving an IL-11-blocking antibody beginning at 75 weeks of age experienced substantial increases in median lifespan.
Males lived approximately 22.5% longer.
Females lived approximately 25% longer.
And lifespan wasn’t the only improvement.
Researchers observed better metabolic health, improved muscle function, reduced frailty, and fewer visible tumors at autopsy.
Mechanistically, IL-11 inhibition influenced ERK, AMPK, and mTORC1 signaling.
That last pathway should sound familiar to anyone following rapamycin and longevity research.
But here’s where things get interesting.
IL-11-targeting therapies have already entered human clinical development.
However, those trials are investigating fibrotic diseases, including pulmonary fibrosis, not aging or lifespan extension.
That’s an important distinction.
We currently have compelling mouse data, but no evidence that IL-11 inhibition extends human lifespan.
The longevity findings also need independent replication.
And while reducing excessive inflammatory signaling sounds beneficial, IL-11 has physiological functions. Chronically suppressing it could introduce consequences that short-term studies won’t detect.
This is why the ongoing human trials are worth watching.
Not because they’ll establish IL-11 inhibition as an anti-aging treatment, but because they’ll help clarify its safety profile and biological effects in humans.
A 25% lifespan extension in mice is remarkable.
Translating that into safe, meaningful benefits for humans is an entirely different challenge.
Promising target? Absolutely.
Proven longevity intervention? Not even close.
#IL11 #Longevity #AgingResearch #Inflammation #mTOR #Rapamycin #Biotechnology #Biohacking #LifeExtension #ElevateBiohacking
Metformin has been around for nearly 70 years, but new research suggests this old diabetes medication might have some interesting effects on the aging brain.
A randomized, double-blind trial from Mayo Clinic, published October 27 in the Journal of Clinical Investigation, examined 40 older adults with insulin resistance over 40 weeks.
Participants received either metformin or placebo, with both groups receiving vitamin B12.
Here’s what researchers observed:
Metformin improved BMI, body fat, fasting glucose, and HbA1c.
Brain glucose uptake increased relative to placebo in four regions rich in insulin receptors, including areas of the prefrontal cortex, retrosplenial cortex, and thalamus.
Whole-brain glucose uptake showed a positive trend but didn’t reach statistical significance (p = 0.086).
A composite score combining processing speed and working memory also improved.
Sounds promising, right?
Here’s where the details matter.
There were only 20 participants per group.
The cognitive composite was constructed post hoc, and the other cognitive measures didn’t demonstrate significant differences.
A conference abstract from the same trial also reported reductions in leg lean mass and a small decline in VO2 peak among participants receiving metformin.
And importantly, this wasn’t a dementia prevention trial. Researchers measured metabolic changes, brain imaging, and cognitive performance over approximately 10 months.
My takeaway?
Not a fan. The brain glucose findings are genuinely interesting. Improving metabolic dysfunction may influence how certain brain regions utilize energy.
But improved glucose uptake isn’t automatically improved cognition, and improved cognition over several months isn’t proof of dementia prevention.
We also shouldn’t ignore potential tradeoffs involving skeletal muscle and aerobic capacity, especially in older adults.
Metformin remains an interesting longevity research candidate for many, but interesting mechanisms aren’t the same as demonstrated longevity benefits. But yeah personally, I’m not a fan at all.
The research continues.
#Metformin #Longevity #BrainHealth #Neuroscience #InsulinResistance #CognitiveHealth ##AgingResearch #Elevateresearch
Cagrilintide: What the Research Shows elevateresearch.blog/2026/10…
Why did ReviveRx have to start sending reconstituted HcG? The 30ml bac water always came in clutch lol
Modafinil: What the Research Shows elevateresearch.blog/2026/10…
Elamipretide (SS-31): What the Research Shows elevateresearch.blog/2026/10…
For years, one of the most widely repeated claims in neuroscience was that humans stop producing new neurons after childhood.
That position has become increasingly difficult to defend.
Recent research suggests that neural progenitor cells persist in the adult human hippocampus, potentially even into old age.
But the scientific debate is more complicated than simply declaring that adults grow new brain cells.
Here’s how the evidence developed.
2018 — The controversy
Sorrells et al., published in Nature, reported that hippocampal neurogenesis declined sharply during childhood and became undetectable in adults.
That same year, Boldrini et al., publishing in Cell Stem Cell, examined brain tissue from 28 individuals aged 14–79.
They identified thousands of immature neurons across the age range.
Two respected research groups. Two dramatically different conclusions.
2019 — Tissue preservation changes the picture
Moreno-Jiménez et al., Nature Medicine, examined hippocampal tissue using carefully controlled preservation methods.
They identified thousands of immature neurons in neurologically healthy individuals up to age 87.
Interestingly, the number of immature neurons declined substantially in Alzheimer’s disease.
This suggested that differences in tissue handling might explain some earlier conflicting findings.
2025 — Stronger evidence emerges
Researchers at Sweden’s Karolinska Institutet, led by Jonas Frisén’s group, published findings in Science.
Using single-nucleus RNA sequencing and machine-learning approaches, they investigated human hippocampal tissue spanning infancy through age 78.
They identified neural progenitor populations, including evidence of proliferating progenitor cells, in adult hippocampal tissue.
This strengthened the argument that the cellular machinery associated with neurogenesis can persist throughout adulthood.
But several questions remain unanswered.
Identifying neural progenitors doesn’t automatically establish how many mature, functional neurons are produced.
We still don’t know the extent to which adult-born neurons integrate into existing neural circuits.
Individual variability appears substantial.
And perhaps most importantly, we don’t know how much adult hippocampal neurogenesis contributes to memory, learning, emotional regulation, or psychiatric health in humans.
Why does this matter for nootropic research?
Because claims about compounds increasing neurogenesis are everywhere.
NSI-189, dihexa, various peptides, and numerous experimental compounds are frequently discussed in this context.
But demonstrating increased neurogenesis in rodents is very different from demonstrating meaningful functional improvements in humans.
A compound might increase neurotrophic signaling, alter progenitor activity, or improve performance in an animal model.
None of those findings automatically establishes that it generates functional new neurons in the adult human brain.
My takeaway:
The evidence increasingly supports the persistence of neural progenitor activity in the adult human hippocampus.
That’s genuinely exciting.
But the next challenge isn’t simply proving these cells exist.
It’s understanding what they actually do, whether their activity can be safely modified, and whether doing so produces meaningful clinical benefits.
The distinction between biological plausibility and demonstrated human outcomes remains essential.
Not medical advice.
#Neurogenesis #Neuroscience #BrainHealth #Nootropics #Neuroplasticity #Longevity #CognitiveHealth #Pharmacology
One of the more interesting neuroprotective compounds in Russian pharmacology is something most people in the United States have probably never heard of.
Emoxypine succinate, commonly marketed as Mexidol.
It’s essentially a substituted hydroxypyridine ring structurally related to vitamin B6, paired with succinate.
What makes this compound interesting is its proposed dual mechanism involving oxidative stress and mitochondrial energy metabolism.
Let’s examine the pharmacology.
1. Antioxidant and neuroprotective activity
The emoxypine component, 2-ethyl-6-methyl-3-hydroxypyridine, has demonstrated several effects in preclinical research:
• Free-radical scavenging activity.
• Increased superoxide dismutase (SOD) activity.
• Increased glutathione peroxidase activity.
• Modulation of Nrf2 signaling under ischemic conditions.
These mechanisms are particularly interesting in neurological conditions involving oxidative stress and impaired cellular metabolism.
2. Mitochondrial metabolism
The succinate component is relevant because succinate participates in mitochondrial energy production through complex II of the electron transport chain.
Succinate also acts as a signaling molecule through SUCNR1, previously known as GPR91.
In aged rats exposed to stress, emoxypine succinate was associated with normalization of cortical PGC-1α and SUCNR1 gene expression.
That suggests potential effects on mitochondrial regulation, although these findings remain preclinical.
What about human research?
The MIR trial is one of the more compelling studies.
This randomized, double-blind, placebo-controlled trial enrolled 304 patients recovering from ischemic stroke.
Emoxypine succinate was administered alongside standard treatment.
Researchers reported improvements in neurological function, disability assessments, and mobility compared with placebo.
Cognitive outcomes showed a favorable trend but were less convincing.
Adverse events occurred in approximately 23% of participants in both groups.
Now the limitations.
Much of the clinical literature originates from Russian research groups and Russian-language publications.
A pooled analysis of 11 stroke studies included only two randomized trials.
Another meta-analysis examining cognitive outcomes relied on comparisons against basic therapy rather than consistently using placebo controls.
And despite its established use in Russia, Mexidol lacks FDA and EMA approval.
My takeaway:
Emoxypine succinate is an interesting example of a compound with plausible antioxidant and mitochondrial mechanisms, supported by some encouraging clinical research.
But promising mechanisms and positive regional clinical trials aren’t substitutes for independent replication.
I’d particularly like to see larger international trials examining neurological recovery, cognitive outcomes, and long-term safety.
There’s enough here to justify scientific interest.
Not enough to make sweeping claims about neuroprotection or cognitive enhancement in healthy individuals.
Not medical advice.
#Emoxypine #Mexidol #Neuroprotection #Nootropics #Neuroscience #Mitochondria #Pharmacology #Biohacking
This might be one of the most scientifically illiterate takes on creatine I’ve seen.
Creatine is one of the most extensively researched supplements in sports nutrition, with decades of evidence supporting its safety and effectiveness in healthy individuals.
First, creatine doesn’t inflate muscles like a balloon. It increases phosphocreatine availability, improving ATP regeneration during high-intensity exercise. The increased water retention is primarily intracellular, not some imaginary inflation of muscle tissue.
Second, creatine improves strength, power output, training capacity, and lean mass gains when combined with resistance training. These are measurable physiological adaptations, not cosmetic illusions.
Third, the claim that creatine causes soft tissue injuries because muscles lack “pure substance” is completely fabricated. Research doesn’t support an increased risk of muscle strains, tendon injuries, or cramping. Some athletic studies actually report fewer injuries among creatine users.
But here’s what makes this take even worse: creatine isn’t exclusively a muscle supplement.
Your brain has enormous energy demands, and the creatine-phosphocreatine system helps maintain cellular ATP availability in neural tissue.
Human research suggests creatine supplementation may improve certain aspects of memory and cognitive performance, particularly in older adults, vegetarians, and individuals experiencing sleep deprivation or metabolic stress. Results in healthy, well-rested young adults are less consistent.
There’s also emerging research investigating creatine’s potential neuroprotective properties and applications in neurological conditions, although clinical benefits remain unproven.
And here’s the funniest part: your body naturally synthesizes creatine, and you consume it through foods like meat and fish. It’s already part of normal human physiology.
Nutrition and sleep are foundational. Nobody disputes that. But pretending they somehow invalidate decades of research on supplementation is ridiculous.
You’re telling elite athletes to abandon one of the most evidence-supported performance supplements available while demonstrating a fundamental misunderstanding of muscle physiology, cellular energetics, and neuroscience.
Creatine isn’t just about building muscle. It’s involved in maintaining energy availability in both skeletal muscle and the brain.
Being loud and confident doesn’t make you scientifically literate.
#Creatine #SportsScience #Neuroscience #CognitivePerformance #Biohacking
I’m telling all athletes…STOP TAKING CREATINE. You don’t need it. Stop putting that nonsense in your body. A good diet and proper sleep are best. Stop letting little Jimmy at the local Planet Fitness tell the top 1% of human bodies what to supplement. Creatine is like filling a balloon with air it looks bigger and better till it’s time to put it under stress. That’s why soft tissue injuries happen. Your muscles lack pure substance.
Readers added context they thought people might want to know
Scientific research and the International Society of Sports Nutrition show no evidence that creatine causes soft tissue injuries or weakens muscles. Studies show creatine users experience an equal or lower incidence of muscle strains and cramping compared to non-users. thegpni.com/articles/show/…
Elevate Research Community retweeted
I suspect that many people who are still obese and resisting GLP1s have this fear because “it can’t be that easy” how can something that costs less than $50-100 a month change your life. It’s hard to believe in miracles when you have struggled with your own body for so long.
Ibutamoren (MK-677): What the Research Shows elevateresearch.blog/2026/10…
I really don’t understand this outlook. I fully support people using all available tools necessary to become healthier versions of themselves.
I get what you’re saying, but even so, a HEALTHY person should never inject this kind of crap into their body. 9 times out of 10, it simply comes down to a lack of discipline and willpower. And these are usually the same people who go for the highest dose because they’re impatient and want “quick results.”
100% (excuse my early repost) lol
For further context, I’m not flat out saying you can’t morning dose, but as I commented once below, it appears a lot of GHRH logic bled into HGH logic on YouTube, Reddit, X, etc when it’s completely different and timing is WAY less important for the food intake, as long as your not eating awhile after (strictly for the small edge of lipolysis HGH offers) alongside its plethora of other benefits.
Again, a small fake edge is the pointed out argument here, not an overall you can’t do this*